Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
10.00
+0.14 (1.42%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Immatics Revenue
In the year 2025, Immatics had annual revenue of 48.27M EUR, down -69.03%. Immatics had revenue of 19.76M in the quarter ending December 31, 2025, a decrease of -64.87%.
Revenue (ttm)
48.27M EUR
Revenue Growth
-69.03%
P/S Ratio
23.66
Revenue / Employee
74,831 EUR
Employees
645
Market Cap
1.34B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 48.27M | -107.57M | -69.03% |
| Dec 31, 2024 | 155.84M | 101.84M | 188.60% |
| Dec 31, 2023 | 54.00M | -118.83M | -68.76% |
| Dec 31, 2022 | 172.83M | 138.07M | 397.17% |
| Dec 31, 2021 | 34.76M | 3.51M | 11.23% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Monte Rosa Therapeutics | 181.54M |
| EyePoint | 31.37M |
| Septerna | 22.05M |
| Zenas BioPharma | 15.00M |
| DBV Technologies | 5.50M |
| AtaiBeckley | 3.02M |
IMTX News
- 10 hours ago - Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot - Seeking Alpha
- 2 months ago - Immatics: PRAME Leader's Transition To Commercial Reality - Seeking Alpha
- 3 months ago - Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress - GlobeNewsWire
- 3 months ago - Immatics Announces $125 Million Underwritten Offering - GlobeNewsWire
- 4 months ago - Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps - GlobeNewsWire
- 4 months ago - Immatics Appoints Amie Krause as Chief People Officer - GlobeNewsWire
- 5 months ago - Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium - GlobeNewsWire
- 5 months ago - Immatics: Multiple Clinical Catalysts In Q4'25 And 2026 - Seeking Alpha